Scholarlink

<p>This study investigated the effects of chitooligosaccharides (COS) on proinflammatory cytokines and nuclear factor-κB (NF-κB) activation in particulate matter 10 (PM10)-induced mice. Results demonstrated that COS treatment significantly reduced proinflammatory cytokines, including interleukin (IL)-6 and IL-1β, particularly in the COS_20 group (20&#xa0;mg/kg body weight of COS). Lower COS doses correlated with a dose-dependent decrease in proinflammatory cytokine levels and inflammatory cell infiltration in bronchoalveolar lavage fluid and lung tissue. COS treatment increased Th2 cell-related biomarkers (IL-4, IL-5, and IL-13), although these decreased at higher doses. Western blotting analysis revealed that COS suppressed NF-κB activation, particularly in the COS_20 group, suggesting that COS may inhibit IκB degradation, preventing NF-κB translocation to the nucleus and subsequent transcription of proinflammatory genes. These findings indicate that COS effectively mitigates the inflammatory response triggered by PM10 exposure, positioning it as a potential functional health supplement for managing pulmonary inflammation and related disorders.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chitooligosaccharides as a potential immune modulator for reducing particulate matter 10-induced inflammation in pulmonary damage models

  • 期刊论文

  • 发表日期：

    2025年8月7日

查看全文
  • Chan-Ho Park,
  • Yun-Ho Kim,
  • Ju Myung Kim,
  • Yeo Cho Yoon

摘要

This study investigated the effects of chitooligosaccharides (COS) on proinflammatory cytokines and nuclear factor-κB (NF-κB) activation in particulate matter 10 (PM10)-induced mice. Results demonstrated that COS treatment significantly reduced proinflammatory cytokines, including interleukin (IL)-6 and IL-1β, particularly in the COS_20 group (20 mg/kg body weight of COS). Lower COS doses correlated with a dose-dependent decrease in proinflammatory cytokine levels and inflammatory cell infiltration in bronchoalveolar lavage fluid and lung tissue. COS treatment increased Th2 cell-related biomarkers (IL-4, IL-5, and IL-13), although these decreased at higher doses. Western blotting analysis revealed that COS suppressed NF-κB activation, particularly in the COS_20 group, suggesting that COS may inhibit IκB degradation, preventing NF-κB translocation to the nucleus and subsequent transcription of proinflammatory genes. These findings indicate that COS effectively mitigates the inflammatory response triggered by PM10 exposure, positioning it as a potential functional health supplement for managing pulmonary inflammation and related disorders.

Graphical abstract